Peer-reviewed veterinary case report
Intermittent doxorubicin treatment for dogs with B-cell lymphoma
By Higginbotham, Mary Lynn et al.·Published in Journal of the American Animal Hospital Association·2013·Department of Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Intermittent single-agent doxorubicin for the treatment of canine B-cell lymphoma.
- Species:
- dog
Plain-English summary
Eighteen dogs with B-cell lymphoma, a type of cancer, were treated with doxorubicin, a common chemotherapy drug, given intermittently. This approach resulted in a complete response rate of 78%, meaning most dogs showed significant improvement. On average, dogs remained in remission for about 80 days, and their overall survival was around 169 days. This treatment option was designed to be more manageable for pet owners concerned about costs and time commitments, although it is not a replacement for more intensive chemotherapy regimens. Many dogs responded well to this treatment, making it a viable option for those facing challenges with traditional therapies.
People also search for: dog lymphoma treatment · doxorubicin for dogs · canine cancer survival rates
Abstract
Canine B-cell lymphoma is a highly treatable disease, but cost and logistical factors may hamper an owner's ability to pursue treatment of their pet with this disease. The authors evaluated the use of single-agent doxorubicin in an intermittent fashion for efficacy in the treatment of this disease. Morphologic and clinical data were analyzed for prognostic significance. Eighteen dogs with B-cell lymphoma, all with multicentric disease, were enrolled. The overall complete response (CR) rate was 78%, median total doxorubicin remission time (TDR) was 80.5 days, and median overall survival (OS) was 169.5 days. The median number of doxorubicin doses administered was 4.5. First remission times were significantly affected by clinical stage and substage of disease. Outcome for the dogs in this study were similar to those previously reported for single-agent doxorubicin treatment. Additionally, the intermittent nature of the treatments made the described protocol more feasible for the owners who enrolled their pets in this study. Intermittent single-agent doxorubicin is not a substitute for multiagent chemotherapy protocols in the treatment of canine lymphoma; however, it is a reasonable alternative if the cost and time commitments are limiting factors for an owner.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24051255/